Figure 2: AN3661 efficacy in murine malaria models | Nature Communications

Figure 2: AN3661 efficacy in murine malaria models

From: A potent antimalarial benzoxaborole targets a Plasmodium falciparum cleavage and polyadenylation specificity factor homologue

Figure 2

(a) AN3661 efficacy in P. berghei-infected mice. Mice (4–5 animals for each concentration tested) were treated orally with the indicated dosages of AN3661, chloroquine or vehicle daily for 4 days. Infections were monitored daily by Giemsa-stained blood smears, and mice were euthanized when parasitemias exceeded 50%. (b) AN3661 efficacy in P. falciparum-infected mice. Mice with 40% circulating human erythrocytes were intravenously infected with 2 × 107 P. falciparum-infected erythrocytes on day 0, and AN3661 was then administered by oral gavage at the indicated dosages for 4 consecutive days (arrows). Parasitemia was measured by flow cytometry daily until day 7. Mean parasitemias for three mice in each group are shown. Error bars represent s.e.m.

Back to article page